Argos Therapeutics Inc. (NASDAQ:ARGS) major shareholder International S. Pharmstandard bought 41,259 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The shares were acquired at an average price of $4.77 per share, for a total transaction of $196,805.43. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Argos Therapeutics Inc. (NASDAQ:ARGS) traded up 7.95% on Wednesday, hitting $5.16. The stock had a trading volume of 187,655 shares. The stock has a 50 day moving average price of $4.80 and a 200 day moving average price of $5.96. The company’s market cap is $212.57 million. Argos Therapeutics Inc. has a 1-year low of $1.61 and a 1-year high of $13.97.

Argos Therapeutics (NASDAQ:ARGS) last released its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. On average, equities research analysts expect that Argos Therapeutics Inc. will post ($1.55) EPS for the current fiscal year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/insider-buying-argos-therapeutics-inc-args-major-shareholder-acquires-41259-shares-of-stock.html

Several equities research analysts recently commented on the company. Zacks Investment Research lowered Argos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. FBR & Co restated a “buy” rating on shares of Argos Therapeutics in a research report on Tuesday, June 14th. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Argos Therapeutics in a research report on Friday, June 17th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $11.00 target price on shares of Argos Therapeutics in a research report on Monday, June 20th. Eight equities research analysts have rated the stock with a buy rating, Argos Therapeutics has an average rating of “Buy” and a consensus target price of $11.50.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. bought a new position in Argos Therapeutics during the second quarter valued at approximately $137,000. Bridgeway Capital Management Inc. increased its position in Argos Therapeutics by 66.9% in the second quarter. Bridgeway Capital Management Inc. now owns 135,924 shares of the biopharmaceutical company’s stock valued at $833,000 after buying an additional 54,500 shares in the last quarter. KCG Holdings Inc. bought a new position in Argos Therapeutics during the second quarter valued at approximately $163,000. State Street Corp bought a new position in Argos Therapeutics during the second quarter valued at approximately $741,000. Finally, BlackRock Institutional Trust Company N.A. bought a new position in Argos Therapeutics during the second quarter valued at approximately $363,000. Hedge funds and other institutional investors own 11.05% of the company’s stock.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

5 Day Chart for NASDAQ:ARGS

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.